Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data & AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma & Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2025 / May / Liver Tissue Analysis Uncovers Key Mechanisms Driving Hepatocellular Carcinoma
Clinical Translational Science Mass Spectrometry Liquid Chromatography

Liver Tissue Analysis Uncovers Key Mechanisms Driving Hepatocellular Carcinoma

A multi-omics study distinguishes two subtypes of chronic liver disease that may progress to liver cancer via distinct molecular pathways

05/07/2025 2 min read

Share

0525-101-AI-News-Uncovering-the-molecular-drivers-of-liver-cancer_Teaser.png

A multi-omics investigation has uncovered distinct molecular patterns in liver tissue affected by non-viral chronic liver disease (CLD), offering insight into how these changes may lead to hepatocellular carcinoma (HCC). The study, led by a team at Hiroshima University and collaborators at Hiroshima Prefectural Hospital, Japan, applied RNA sequencing and metabolomics to paired liver samples from patients with and without HCC, leading to the identification of two mechanistically distinct CLD subtypes.

The researchers analyzed non-cancerous liver tissue adjacent to tumors in patients with CLD, using RNA sequencing to quantify gene expression and liquid chromatography-mass spectrometry to identify metabolite profiles. This approach allowed them to examine the interplay between transcriptomic alterations and metabolic dysfunction, revealing insights on potential cancer-promoting pathways.

“Through multi-omics analysis of transcriptomic and metabolomic data, we aimed to uncover molecular mechanisms underlying HCC development and identify novel targets for chemoprevention,” said first author Hikaru Nakahara in the team’s press release.

Subtype 1 – a cohort of relatively younger patients – exhibited upregulation of inflammation-related gene expression and signaling pathways, including cytokine-cytokine receptor interactions. In contrast, Subtype 2 – containing older patients – showed evidence of age-related metabolic decline, including reduced fatty acid oxidation and increased accumulation of lipid metabolites. Both subtypes demonstrated downregulation of genes related to peroxisome and mitochondrial function.

The team also assessed the potential of therapeutic intervention using published data from a murine model. In mice fed a high-fat diet to induce non-alcoholic fatty liver disease, inflammatory gene expression was suppressed when the antioxidant epigallocatechin gallate (EGCG), a green tea catechin, was supplemented. The authors propose that EGCG or related compounds may have clinical utility in modifying CLD-related cancer risk, though further studies are needed.

"The molecular mechanisms underlying the development of HCC from CLD have been shown to involve activation of inflammation-related signals and age-related metabolic abnormalities. It is suggested that there is a need to distinguish targets for chemoprevention based on these different mechanisms,” said Atsushi Ono, co-author of the study. “In addition, it has been suggested that supplementation with antioxidants, such as epigallocatechin gallate (EGCG), may be effective in ameliorating these abnormalities.”

Looking ahead, the researchers aim to translate these molecular findings into tailored preventive strategies for patients with CLD. “In the future, we hope that treatments will be developed that are tailored to molecular abnormalities, such as eliminating inflammation in the [CLD] group characterized by inflammation, and replenishing [metabolites] that become deficient with age in the [CLD] group characterized by aging,” said Ono.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.